A single study is proposed to address both European Union followup measures with the following objectives:
1. To quantify and characterise off-label use through an evaluation of the disease and characteristics of patients treated with MabThera for non-oncology conditions.
2. To evaluate the extent to which patients receive and read the Patient Alert Card (PAC), knowledge of the PAC content among patients receiving MabThera for non-oncology conditions at infusion centres,
and whether distribution of the PAC may influence patient actions.